YT-HBV-x

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameYT-HBV-x
Drug Alias NameHBV TCR-Tanti-HBV TCR T-cell therapy (China Immunotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHBsAg modulatorsHuman leukocyte antigen modulators
TargetsHuman leukocyte antigenHepatitis B Surface Antigens
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, HepatocellularHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Immunotech Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, HepatocellularHepatitis B
Inactive IndicationsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A